RNA therapeutics
RNA interference could become the standard of care for lipid disorders, review of siRNA therapeutics beyond LDL-C (Curr Opin Lipidol 2026)
Original title: RNA interference for lipid disorders: is this the future?
Review of RNA interference (RNAi) therapeutics in lipid management. Inclisiran, the first approved RNAi therapy for hypercholesterolaemia, achieves about 50% sustained LDL-C reduction with infrequent dosing, an alternative to monoclonal antibodies. Beyond LDL-C, multiple siRNA drugs in advanced development target lipoprotein(a), apolipoprotein C-III and angiopoietin-like protein 3 to address residual cardiovascular risk; early safety and adherence data are encouraging, though pivotal outcome trials and cost-effectiveness analyses are still pending. The authors argue siRNA-based therapies are a disruptive technology that could become foundational in personalised lipid management, moving the field toward long-acting, target-specific and combination regimens, if ongoing trials confirm cardiovascular benefit and safety.
Original abstract
Purpose Of Review: Advances in the management of lipid disorders have expanded therapeutic options for hypercholesterolemia and beyond. We review the current advances in RNA interference (RNAi) therapies as small interfering RNA (siRNA) drugs, critically assess their clinical positioning, and explore their potential role in reshaping lipid management over the next years.
Recent Findings: RNAi enables targeted, durable suppression of key lipid-regulating proteins at the mRNA level. Inclisiran, the first approved RNAi therapy for hypercholesterolemia, achieves about 50% sustained LDL-c reduction with long-interval maintenance dosing, offering an alternative to monoclonal antibodies. Beyond LDL-c lowering, multiple RNAi drugs are in advanced development targeting lipoprotein(a), apolipoprotein C-III, and angiopoietin-like protein 3, aiming to address residual cardiovascular risk. Early safety and adherence data are encouraging, yet pivotal outcome trials and cost-effectiveness analyses are still pending.
Summary: RNAi is a naturally occurring gene-silencing mechanism that can be harnessed therapeutically through siRNA molecules. In lipidology, siRNA-based therapies represent a disruptive technology with the potential to transform both prevention and treatment of atherosclerotic cardiovascular disease. If ongoing trials confirm cardiovascular benefit and safety, RNAi agents could become foundational in personalized lipid management, moving the field toward long-acting, target-specific, and potentially combination-based regimens. The coming years will determine whether RNAi fulfills its promise as the future standard of care in lipid disorders.
Summary written by lp-a.org from the published abstract; figures as published. Page updated 17 August 2026. Methods.